December 12, 2024

Innovation Prize 2025 of the German BioRegions – Application Deadline: February 14, 2025

Innovators wanted. APPLY NOW!
WE SUPPORT YOUR INNOVATIVE INVENTION!

The work group of the BioRegions in Germany is the central network of regional initiatives promoting the economic use of modern biotechnologies in Germany. It annually awards the Innovation Prize of the BioRegions in Germany. This year, the work group again recognizes application-oriented ideas with strong implementation potential and showcases them at the German Biotech Days.

What is awarded?

The Innovation Prize honors innovative ideas that are patented or have been submitted for patenting.
We seek application-oriented ideas with strong implementation potential and high market opportunities.
Our aim is to support outstanding innovations that can significantly contribute to the economy and society.

Who can apply?

Scientists from universities and non-university institutions
Legal entities under public law, such as universities, universities of applied sciences, or patent exploitation agencies
Founders of companies that have not yet generated significant revenue and have not transferred substantial company shares to external investors

What do we offer?

Invitation for six finalists to the German Biotech Days on April 9 and 10, 2025, in Heidelberg
Presentation to an international audience, financiers, and the trade press
Three awards, each worth €2,000
An audience award worth €2,000

Apply now!

Application Deadline: February 14, 2025.

TO THE APPLICATION

Innopreis_2025_Flyer_E Download

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

Common cough syrup ingredient shows promise in treating serious lung disease

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions. Scientists from EMBL Heidelberg were part of a […]

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]